‌

US Patent 11492351 MTA-cooperative PRMT5 inhibitors

Patent 11492351 was granted and assigned to Mirati Therapeutics on November, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

Mirati Therapeutics

Current Assignee

Mirati Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

114923510

Patent Inventor Names

John David Lawson0

Christopher Ronald Smith0

Aaron Craig Burns0

Anthony Ivetac0

Thomas P. Bobinski0

Svitlana Kulyk0

Matthew Arnold Marx0

Jon Kuehler0

...

Date of Patent

November 8, 2022

Patent Application Number

170187380

Date Filed

September 11, 2020

Patent Primary Examiner

CPC Code

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11492351 MTA-cooperative PRMT5 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API